OCUL
Ocular Therapeutix
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 1
consensus rating "Buy"
EPS Beats Expectation
Revenue Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About OCUL
Ocular Therapeutix, Inc.
A biopharmaceutical company focused on innovative therapies for diseases and conditions of the eye
15 Crosby Drive, Bedford, MA 01730
--
Ocular Therapeutix, Inc., was established in Delaware on September 12, 2006. The company is a biopharmaceutical company dedicated to improving people's vision and quality of life by developing and commercializing innovative therapies for eye diseases and conditions, with a special focus on retinal diseases. The company's hydrogel-based bioabsorbable product candidate is designed to provide sustained release of therapeutic drugs to the eye. The Company's lead product candidates are drug-eluting punctal plug OTX-DP and punctal OTX-TP inserted into a natural opening called the punctum located on the inner part of the eyelid near the nose. The Company's canalicular suppository product candidate combines the Company's hydrogel technology with the U.S. Food and Drug Administration, or FDA-approved therapeutic drug for the purpose of providing continuous dosing to the eye.
Company Financials
EPS
OCUL has released its 2024 Q4 earnings. EPS was reported at -0.29, versus the expected -0.22, missing expectations. The chart below visualizes how OCUL has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
OCUL has released its 2024 Q4 earnings report, with revenue of 17.08M, reflecting a YoY change of 15.41%, and net profit of -48.39M, showing a YoY change of -65.60%. The Sankey diagram below clearly presents OCUL’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
